Barcelona expect Xavi Espart to be unavailable for around seven weeks after tests confirmed an injury to the syndesmosis joint in his right ankle. The club announced the diagnosis on Monday 26 October, turning the uncertainty over the defender's condition into a substantial confirmed availability setback for Hansi Flick.
The official medical bulletin attributes the injury to a collision with an opposing player during the match against Real Madrid. The new development is the assessment issued after examinations, rather than the fact that Espart had been hurt during Sunday's game. Barcelona have now supplied both the affected area and an approximate absence.
What Barcelona have confirmed
The club identifies the right ankle's syndesmosis joint and gives a recovery estimate of around seven weeks. It does not announce a specific return fixture, an operation or a date for resuming full training. Those details should therefore remain open rather than being inferred from the length of the expected lay-off.
Seven weeks from 26 October points approximately to mid-December, but that is a calendar calculation, not a promised comeback. The distinction matters when assessing future selection: an estimate describes the expected interruption, while a confirmed return would require a later update. This report does not assign Espart a medical clearance date.
The immediate fixtures affected
Barcelona's official first-team schedule lists Alaves at home on Saturday 31 October, followed by Aston Villa at home in the Champions League on Tuesday 3 November. Both kick off at 8pm GMT for UK viewers. Those matches fall well within the newly announced absence estimate.
The next league visit is to Atletico Madrid on Sunday 8 November, also listed for 8pm GMT. Later November commitments include Villarreal at home and a European trip to Sabah. These dates illustrate why this is more than a one-match selection problem: the published timetable spans domestic and European duties rather than one isolated competition.
It would nevertheless be premature to count an exact number of missed appearances across the whole recovery period. Fixture schedules and individual availability updates remain relevant. The immediate planning implication is clear without producing a speculative return-day team sheet: Flick must prepare his next matches without relying on Espart's quick recovery.
A setback during a significant breakthrough
The interruption comes shortly after Barcelona highlighted the full-back's development in a club feature published on 21 October. That account described his first senior European goal against Paris Saint-Germain and his contribution at both ends of the pitch. It provides context for the footballing loss without treating the previous match as today's news.
In that Champions League appearance, Barcelona credited Espart with eight recoveries and two defensive clearances, as well as his goal. Those are figures for that particular game, not season totals or an assessment of how another defender will perform in his place. They underline the range of work the club had recently praised.
Longer-term commitment remains the background
On 8 October, Barcelona announced an agreement to extend Espart's contract to 30 June 2030. That statement said formal signing would follow. It also traced his route from joining La Masia in summer 2015 to making his senior debut under Flick in March 2026 at Newcastle in the Champions League.
The same announcement recorded six senior appearances in the 2025/26 campaign and confirmation of his full first-team squad status on 27 August. These are dated milestones in his progression, not updated appearance totals. The injury now interrupts a period in which the club had been establishing his longer-term place in the squad.
What to watch next
Barcelona have also recently confirmed a separate absence for Dani Olmo, covered in our report on his adductor injury. The two cases should not be combined into a single recovery timetable. For Espart, the next useful information will be a club update on rehabilitation or selection availability, not an assumed return based solely on counting seven weeks.
